Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Net Income (2016 - 2025)

Fate Therapeutics' Net Income history spans 14 years, with the latest figure at -$32.5 million for Q4 2025.

  • For Q4 2025, Net Income rose 43.84% year-over-year to -$32.5 million; the TTM value through Dec 2025 reached -$136.7 million, up 29.19%, while the annual FY2025 figure was -$136.7 million, 29.19% up from the prior year.
  • Net Income reached -$32.5 million in Q4 2025 per FATE's latest filing, down from -$32.2 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$24.9 million in Q1 2023 to a low of -$84.6 million in Q3 2022.
  • Average Net Income over 5 years is -$51.1 million, with a median of -$46.8 million recorded in 2023.
  • Peak YoY movement for Net Income: tumbled 109.01% in 2021, then surged 66.38% in 2023.
  • A 5-year view of Net Income shows it stood at -$69.1 million in 2021, then grew by 10.92% to -$61.5 million in 2022, then rose by 29.05% to -$43.7 million in 2023, then crashed by 32.55% to -$57.9 million in 2024, then soared by 43.84% to -$32.5 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Net Income are -$32.5 million (Q4 2025), -$32.2 million (Q3 2025), and -$34.0 million (Q2 2025).